1 hour ago
1
koto_feja
Shares of Compass Therapeutics (NASDAQ:CMPX) added ~21% on Monday after the cancer drug developer, with its Q2 2025 results, announced a lower-than-expected number of mortalities in a Phase 2/3 trial for its lead asset tovecimig in biliary tract cancer.
Citing
© FBT Company 2025. All rights are reserved
English (US) ·